Abstract
Introduction

Angiogenesis is the process of generating new capillary blood vessels. In the adult, angiogenesis occurs under tight regulation in the female reproductive system and during wound healing. Uncontrolled neovascularization is observed in tumour growth and in angioproliferative diseases
. Tumours cannot grow larger than a few square millimetres as a mass unless a new blood supply is induced [2] . Hence the control of the neovascularization process may affect tumour growth and represents a novel approach to angiogenesis-dependent disease therapy, including neoplasia [3] .
Fibroblast growth factor-2 (FGF2) is a major heparin-binding angiogenic growth factor that induces cell proliferation, chemotaxis and protease production in cultured endothelial cells [4] . In vivo, FGF2 shows angiogenic activity in different experimental models [5] and modulates neovascularization during wound healing, inflammation, atherosclerosis and tumour growth [6] , thus representing a possible target for anti-angiogenic therapies [7, 8] .
Accordingly, preclinical studies demonstrate that FGF2 antagonists inhibit tumour growth and vascularization [8] [9] [10] . [11] and low affinity heparan sulphate proteoglycans (HSPGs) [12, 13] [15] [16] [17] [18] [19] [20] [21] [22] . Similarly, FGF2-binding peptides have been identified as in vitro and/or in vivo FGF2 antagonists [23] [24] [25] . [26, 27] . Recent observations have shown that PTX3 binds FGF2 with high affinity and specificity [28] . Accordingly, PTX3 inhibits FGF2-dependent endothelial cell proliferation in vitro and angiogenesis in vivo [28] . Also, PTX3 inhibits FGF2-dependent smooth muscle cell activation and intimal thickening after arterial injury [29] . [30] .
FGF2 exerts its activity on endothelial cells by interacting with high affinity tyrosine-kinase FGF receptors (FGFRs)
The pattern recognition receptor pentraxin 3 (PTX3) is the prototypic member of the long PTX family. It shares the C-terminal PTX domain with short PTXs and possesses a unique N-terminal domain. The biological activity of PTX3 is related to its ability to interact with different ligands via its N-terminal or C-terminal domain as a consequence of the modular structure of the protein
An integrated approach that utilized PTX3-related synthetic peptides, monoclonal antibodies and surface plasmon resonance analysis has identified a FGF2-binding domain in the N-terminal extension of PTX3 spanning the PTX3-(97-110) region, thus suggesting that synthetic peptides related to the PTX3-(97-110) sequence may represent novel PTX3-derived FGF2 antagonists
Here, we have investigated the ability of various PTX3-(97-110)-related synthetic peptides to interact with FGF2. The results identify the short acetylated (Ac) pentapeptide Ac-ARPCA-NH2 (in single letter code), corresponding to PTX3-(100-104) sequence, as the minimal FGF2-binding peptide able to interfere with FGF2/FGFR interaction. Accordingly, the peptide is endowed with a significant FGF2-antagonist activity in vitro and in vivo. Nuclear magnetic resonance (NMR) analysis of the interaction mode of Ac-ARPCA-NH2 with FGF2 points to a pivotal role of the N-terminal blocking methyl group and of the methyl group of the side chain of Ala5 residue in FGF2 interaction. These results will provide the basis for the design of novel PTX3-derived FGF2 antagonists.
Methods
Chemicals
Human recombinant FGF2, human recombinant PTX3 and synthetic PTX3-derived peptides (HPLC purity Ն95%) were provided by Tecnogen (Piana di Monteverna, Caserta, Italy). FGF2 and PTX3 were expressed in Escherichia coli and Chinese hamster ovary (CHO) cells, respectively, and purified as described [31, 32] 
Cell cultures
Foetal bovine aortic GM7373 endothelial cells [28] [35] . Tumorigenic, FGF2-overexpressing murine aortic endothelial FGF2-T-MAE cells [36] were grown in DMEM plus 10% FCS.
Cell proliferation assays
GM7373 cell proliferation assay was performed as described [37] . Briefly 
FGF2-mediated cell-cell adhesion assay
This assay was performed as described previously [38] 
Western blot analysis
Mitogen-activated protein kinase (ERK1/2) phosphorylation assay was performed as described [34] 
Zebrafish/tumour xenograft angiogenesis assay
This was performed as described previously [41, 42] [28] . On this basis, ARPCA was assessed for its capacity to affect the proliferation of endothelial GM7373 cells exposed to different mitogenic stimuli. In these and following biological experiments, the inactive Ac-ARPSA-NH2 (hereafter referred to as ARPSA) was used as a negative control peptide. As shown in Fig. 1(A [35] (Fig. 1B) [38] . As shown in Fig. 2(A) [34] , thus demonstrating the capacity of the peptide to affect FGFR signalling (Fig. 2B) . Fig. 2 Fig. 1A ). 
To assess whether the inhibition of HSPG/FGF2/FGFR1 complex formation by ARPCA is due to its ability to hamper HSPG/FGF2 and/or FGF2/FGFR1 interactions, the peptide was investigated for the capacity to prevent the binding of free FGF2 to heparin or to a sFGFR1(IIIc)/Fc chimera both immobilized to BIAcore sensor chips. As shown in
(C), ARPCA does not affect FGF2/heparin interaction (ID50 Ͼ 1.0 mM) whereas it significantly inhibits the binding of FGF2 to the immobilized receptor with a potency (ID50 ϭ 30 M) similar to that found when the peptide was tested for its capacity to inhibit FGF2-mediated endothelial cell proliferation (ID50 ϭ 15 M, see Table 1). No effect was instead exerted by ARPSA on both sensor chips. In a control experiment, ARPCA did not prevent the binding of VEGF to an immobilized sKDR/Fc chimera (data not shown), in keeping with the incapacity of the peptide to affect the mitogenic activity exerted by VEGF on endothelial cells (see
Taken together these data indicate that the FGF2 antagonist activity of ARPCA is related to its ability to interfere with
FGF2/FGFR1 interaction without affecting the ability of the growth factor to interact with heparin/HSPGs. This results in the impairment of the formation of a productive HSPG/FGF/FGFR ternary complex, with consequent inhibition of FGFR signalling and FGF2-mediated biological activity.
ARPCA peptide inhibits the angiogenic activity of FGF2 in vivo
In a first set of experiments, the capacity of ARPCA to affect FGF2-induced neovascularization in vivo was investigated in a chick embryo CAM assay [48] . (Fig. 3A) . [41, 42] Ac-PARAC-NH2 1000 Ͼ1000
In this assay, alginate beads adsorbed with FGF2 (8.0 pmoles/embryo) exert a potent angiogenic response when compared with beads adsorbed with vehicle (macroscopic vessels converging towards the implant being equal to 36 Ϯ 4 and 6 Ϯ 3 vessels/embryo, respectively). In keeping with the in vitro observations, the angiogenic response elicited by FGF2 was significantly reduced by the addition of 117 nmoles of ARPCA peptide in the FGF2 implants (17 Ϯ 7 vessels/embryo, P ϭ 0.007). No effect was instead exerted by control ARPSA (33 Ϯ 5 vessels/embryo)
In a second set of experiments, ARPCA and ARPSA were characterized for their ability to affect the angiogenic response triggered by tumorigenic FGF2-overexpressing mouse aortic endothelial (FGF2-T-MAE) cells in a novel zebrafish embryo/tumour graft model
. To this purpose, FGF2-T-MAE cells were resuspended in Matrigel in the absence or in the presence of the peptide under test (300 fmoles/embryo). Then, cells were microinjected in zebrafish embryos at 48 hrs after fertilization
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(1000-2000 cells/embryo) through the perivitelline space between the yolk and the periderm (duct of Cuvier area), close to the developing subintestinal vessels (SIV). As shown in
Fig. 2 Effect of Ac-ARPCA-NH2 on the HSPG/FGF2/FGFR1 complex and FGFR signaling. (A) HSPG-deficient, FGFR1-transfected CHO cells were added to wild-type CHO-K1 monolayers in serum-free medium with FGF2 (1.66 nM) in the presence of Ac-ARPCA-NH2 (᭹) or Ac-ARPSA-NH2 (᭺) peptides. After 2 hrs of incubation at 37ЊC, the cells bound to the monolayer were counted under an inverted microscope. Experiments were performed in triplicate and were repeated twice with similar results. (B)
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Discussion
PTX3 comprises a PTX-like C-terminal 203-amino acid domain
and an N-terminal 178 amino acid extension with no significant homology with any other protein [26] . Previous observations had shown that PTX3 binds FGF2 with high affinity and selectivity, thus hampering the interaction of the growth factor with its cell surface receptors and inhibiting its activity on target cells [28] . Indeed, PTX3 suppresses the angiogenic activity exerted by FGF2 on endothelial cells [27] and prevents FGF2-dependent smooth muscle cell activation [29] , thus representing an endogenous FGF2 inhibitor in different pathophysiological settings and a candidate for the design of novel specific FGF2 antagonists [27] . FGF2 interaction is mediated by the linear amino acid sequence PTX3-(97-110) present in the N-terminal extension on PTX3 [30] . Accordingly, the synthetic peptide 
